Pacira BioSciences
PCRX
261 hedge funds and large institutions have $1.65B invested in Pacira BioSciences in 2023 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 88 increasing their positions, 92 reducing their positions, and 38 closing their positions.
114% more call options, than puts
Call options by funds: $12.8M | Put options by funds: $5.96M
14% more capital invested
Capital invested by funds: $1.46B → $1.65B (+$199M)
3.52% more ownership
Funds ownership: 102.08% → 105.6% (+3.5%)
5% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 38
0% more funds holding
Funds holding: 261 → 261 (0)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
4% less repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 92
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$30.5M |
| 2 |
Morgan Stanley
New York
|
+$26.6M |
| 3 |
BlackRock
New York
|
+$17.8M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$8.34M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$4.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$27.9M |
| 2 |
Jennison Associates
New York
|
-$19.1M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$16.8M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$12.7M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$8.13M |
PCRX Hedge Fund Activity: Q4 2023 in Review
261 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q4 2023, worth a combined $1.65B — up 14% from $1.46B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new PCRX positions and 38 closed out — a net gain of 2 holders — while 88 added to existing stakes and 92 trimmed.
The largest buyer was Pacer Advisors, adding an estimated $30.5M. The largest seller was Prosight Management, cutting an estimated $27.9M.
- 261 institutional investors held Pacira BioSciences (PCRX) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $1.65B of Pacira BioSciences stock for Q4 2023, up 14% quarter-over-quarter.
- 40 funds opened new Pacira BioSciences positions in Q4 2023 and 38 closed out, a net change of +2 holders.
- The largest Pacira BioSciences buyer in Q4 2023 was Pacer Advisors, an estimated $30.5M added.
- The largest Pacira BioSciences seller in Q4 2023 was Prosight Management, an estimated $27.9M sold.
Based on aggregated 13F filings for Q4 2023.